BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 16170190)

  • 1. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Node positive renal cell cancer. Who can be helped?
    Messing EM
    Eur Urol; 2007 Jun; 51(6):1477-8. PubMed ID: 17240037
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebuttal from authors re: Edward M. Messing. Node positive renal cell cancer. Who can be helped? Eur Urol 2007;51:1477-8.
    Karakiewicz P; Perrotte P; Trinh QD; Patard JJ
    Eur Urol; 2007 Jun; 51(6):1478-80. PubMed ID: 17275988
    [No Abstract]   [Full Text] [Related]  

  • 6. Current clinical trials in renal cell carcinoma.
    Sokoloff MH; Daneshmand S; Ryan CW
    Urol Oncol; 2005; 23(4):289-92. PubMed ID: 16018946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 8. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is simple enucleation a minimal partial nephrectomy responding to the EAU guidelines' recommendations?
    Ficarra V; Galfano A; Cavalleri S
    Eur Urol; 2009 Jun; 55(6):1315-8. PubMed ID: 18801609
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebuttal from authors re: Vincenzo Ficarra, Antonio Galfano and Stefano Cavalleri. Is simple enucleation a minimal partial nephrectomy responding to the EAU guidelines' recommendations? Eur Urol 2009;55:1315-8.
    Minervini A; Serni S; Di Cristofano C; Carini M
    Eur Urol; 2009 Jun; 55(6):1319-20. PubMed ID: 18804906
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of lymph node dissection in renal cell carcinoma.
    Delacroix SE; Chapin BF; Wood CG
    Urol Clin North Am; 2011 Nov; 38(4):419-28, vi. PubMed ID: 22045173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.
    Harshman LC; Srinivas S
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1749-61. PubMed ID: 18062749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting cancer-control outcomes in patients with renal cell carcinoma.
    Karakiewicz PI; Hutterer GC
    Curr Opin Urol; 2007 Sep; 17(5):295-302. PubMed ID: 17762620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma: vena caval involvement.
    Boorjian SA; Sengupta S; Blute ML
    BJU Int; 2007 May; 99(5 Pt B):1239-44. PubMed ID: 17441917
    [No Abstract]   [Full Text] [Related]  

  • 18. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
    Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.